LOXAPINE inhalation powder (AdasuveĀ®)

Clinical Indication

Rapid control of mild-moderate agitation in schizophrenia or bipolar disorder


Not yet reviewed

Date of classification

September 2016

Review date

September 2019


Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.

All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.